Truist Securities has initiated coverage on MannKind Corp (MNKD) with a Buy rating, effective November 23, 2025. The current share price stands at $5.13.
MannKind Corp is a biopharmaceutical company based in Danbury, Connecticut, focusing on the development and commercialization of innovative therapeutic products for unmet medical needs in endocrine and orphan lung diseases. The company's commercial assets include Afrezza, an inhaled insulin product, and Tyvaso DPI, used in treating pulmonary arterial hypertension.
MannKind's market capitalization is approximately $1.5 billion, with a trailing twelve-month price-to-earnings (P/E) ratio of 53.39 and earnings per share (EPS) of $0.09. The company is scheduled to report its next earnings results on August 4, 2026, with an estimated EPS of $0.02 and revenue of $105.2 million.
Analyst consensus reflects a Buy rating, with 5 Strong Buy, 8 Buy, and 1 Hold among 14 total ratings as of November 1, 2025. Recent analyst actions include Truist's initiation and a maintenance of Outperform by RBC Capital on November 11, 2025, indicating a positive outlook for the company’s performance in the biotechnology sector.